Abbott Laboratories (ABT) Stock Forecast & Price Target

$101.33 +0.26 (+0.26%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$101.26 -0.07 (-0.07%)

As of 09/25/2026 07:59 PM Eastern

Compare

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 27 Analyst Ratings

Sell
0

Hold
4

Buy
23

Based on 27 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 4 have given a hold rating, 20 have given a buy rating, and 3 have given a strong buy rating for ABT.

Consensus Price Target

$119.50
17.93% Upside

According to the 27 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $119.50. The highest price target for ABT is $143.00, while the lowest price target for ABT is $92.00. The average price target represents a forecasted upside of 17.93% from the current price of $101.33.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABT Analyst Ratings Over Time

Type	Current Forecast 9/27/25 to 9/27/26	1 Month Ago 8/28/25 to 8/28/26	3 Months Ago 6/29/25 to 6/29/26	1 Year Ago 9/27/24 to 9/27/25
Strong Buy	3 Strong Buy rating(s)	3 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	20 Buy rating(s)	20 Buy rating(s)	19 Buy rating(s)	16 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$119.50	$119.50	$118.30	$145.22
Forecasted Upside	17.93% Upside	6.10% Upside	27.51% Upside	8.68% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Abbott Laboratories Stock vs. The Competition

Type	Abbott Laboratories	Healthcare Companies	Broader Market
Consensus Rating Score	2.96	2.31	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	17.93% Upside	764.10% Upside	19.20% Upside
News Sentiment Rating	Positive News See Recent ABT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/18/2026	Weiss Ratings 5 of 5 stars		Upgrade	Hold (C-) ➝ Hold (C)
9/8/2026	TD Cowen 3 of 5 stars	Joshua Jennings Not Rated	Reiterated Rating	Buy	$135.00	+26.01%
8/13/2026	Wolfe Research 4 of 5 stars	Mike Polark Not Rated	Upgrade	Peer Perform ➝ Outperform	$130.00	+17.20%
7/28/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$135.00 ➝ $125.00	+16.39%
7/17/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$108.00 ➝ $112.00	+12.14%
7/17/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$115.00 ➝ $118.00	+18.35%
7/17/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$110.00 ➝ $120.00	+18.76%
7/17/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$109.00 ➝ $112.00	+10.49%
7/17/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$130.00	+31.57%
7/17/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marie Thibault Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$131.00 ➝ $134.00	+35.61%
Get the Latest News and Ratings for ABT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter.
7/1/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rescott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$121.00	+33.44%
6/12/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$120.00 ➝ $102.00	+14.47%
5/27/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$121.00 ➝ $113.00	+30.87%
4/22/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$92.00	-0.89%
4/21/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$140.00 ➝ $125.00	+30.13%
4/21/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Market Perform	$119.00 ➝ $106.00	+10.35%
4/20/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$144.00 ➝ $143.00	+47.59%
4/17/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$125.00 ➝ $110.00	+15.70%
4/17/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$134.00 ➝ $120.00	+26.22%
4/17/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$130.00 ➝ $115.00	+20.96%
4/17/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$125.00 ➝ $115.00	+20.96%
4/17/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$145.00 ➝ $135.00	+41.99%
4/17/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Suraj Kalia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$132.00 ➝ $115.00	+20.96%
4/17/2026	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bruce D. Jackson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$145.00 ➝ $120.00	+26.22%
4/17/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$145.00 ➝ $120.00	+26.22%
1/29/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
11/20/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
7/15/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Lewis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$127.00 ➝ $137.00	+3.75%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:37 PM ET.

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 25, 2026. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

Abbott Laboratories recently announced an exclusive partnership with Berry Street that combines the company's Lingo over-the-counter continuous glucose monitor with Berry Street's insurance-covered registered-dietitian and nutrition-coaching platform, a move that could improve Lingo adoption, expand Abbott's consumer health ecosystem, and strengthen its position in metabolic-health services.
The company's Volt Pulsed Field Ablation System reportedly saw its first clinical use in Canada and at an Illinois heart center for treating atrial fibrillation, and additional real-world use could support the medical-device pipeline and future cardiovascular revenue growth.
Abbott Laboratories reported $1.31 earnings per share for the quarter ended July 16th, topping the consensus estimate of $1.28 by $0.03, while the firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion, with revenue up 13.0% compared to the same quarter last year.
Investor commentary continues to describe Abbott as a high-quality, diversified healthcare business with attractive long-term prospects, as its exposure to diagnostics, medical devices, nutrition and digital health provides multiple growth avenues, and the therapeutic drug-monitoring market is projected to expand substantially through 2032.
Abbott Laboratories currently trades at a stock price of $101.33, which is below the average analyst price target of $119.50 and the consensus rating of Moderate Buy, suggesting potential upside for investors.

Abbott Laboratories
Bear Case

Investors should be bearish about investing in Abbott Laboratories for these reasons:

Abbott agreed to pay approximately $385 million to settle infant-formula litigation, and although the settlement removes some legal uncertainty, the cash cost and reputational overhang are negative for near-term sentiment.
Valuation comparisons with faster-growing healthcare companies, including Exact Sciences, may reduce enthusiasm among growth-oriented investors, as Abbott's P/E ratio of 32.79 is higher than some peers.
QRG Capital Management Inc. decreased its stake in shares of Abbott Laboratories by 28.7% during the second quarter, selling 83,416 shares, and Envestnet Asset Management Inc. trimmed its position by 23.7% in the 2nd quarter, selling 1,228,773 shares, indicating some institutional investors are reducing their exposure.
Abbott Laboratories is facing segment competition and sluggish nutrition recovery, as noted in a second-quarter 2026 investor letter from Tributary Capital Management, which highlighted that the fund's equity allocation underperformed in Q2, returning +12.5% against +15.3% for the S&P 1500 and +15.4% for the Russell 3000.
The company's dividend payout ratio (DPR) is presently 81.55%, which is relatively high and may limit its ability to reinvest in growth or weather economic downturns.

ABT Forecast - Frequently Asked Questions

According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $119.50, with a high forecast of $143.00 and a low forecast of $92.00.

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 4 hold ratings, 20 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABT shares.

According to analysts, Abbott Laboratories's stock has a predicted upside of 17.93% based on their 12-month stock forecasts.

Over the previous 90 days, Abbott Laboratories's stock had 5 upgrades and 1 downgrade by analysts.

Abbott Laboratories has been rated by research analysts at BTIG Research, Citigroup, JPMorgan Chase & Co., Piper Sandler, Robert W. Baird, Royal Bank Of Canada, TD Cowen, UBS Group, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Analysts like Abbott Laboratories more than other "healthcare" companies. The consensus rating for Abbott Laboratories is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ABT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Abbott Laboratories Recommendations

MarketBeat monitors more than a dozen sources for Abbott Laboratories analyst ratings, with the most recent rating issued on 9/18/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abbott Laboratories (ABT) Stock Forecast & Price Target